Astrazeneca Announces First Patient Enrolled In Head-To-Head Comparison Of CRESTOR/Ezetimibe With SIMVASTATIN/Ezetimibe
AstraZeneca announced enrollment of the first patient in the new GRAVITY study (Gauging the lipid effects of RosuvAstatin plus ezetimibe Versus sImvastatin plus ezetimibe TherapY).
